- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
PPI use among hospitalized patients tied to risk of colonization with multidrug-resistant bacteria: JAMA
Netherlands: A recent study published in JAMA Network Open has shown that the use of proton pump inhibitors (PPIs) among adult hospitalized patients is linked to an increased risk of acquiring multidrug-resistant bacteria. PPIs are medications used to control heartburn and other gastrointestinal issues.
The study showed that hospitalized patients using proton pump inhibitors had a 50% greater risk of acquiring extended-spectrum beta-lactamase (ESBL)- or carbapenemase-producing Enterobacterales. Patients who used PPIs twice a day had a slightly higher risk.
The findings reinforce the need to promote the judicious PPIs use to lessen the risk of acquiring drug-resistant Enterobacterales among hospitalized patients.
Resistance to ESBLs and carbapenemases is recognized as an increasingly significant problem for public health. Concerns have risen that PPIs, which are widely overused (about 30%-50% are overprescribed), may increase the colonization risk with drug-resistant microorganisms. Possible confounding by lifestyle-associated factors and disease severity casts doubt on this association, and whether the risk is dose-dependent is unknown.
Against the above background, Roel P. J. Willems from Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands, and colleagues aimed to assess the association between the use of PPIs and the risk of acquiring drug-resistant Enterobacterales and to examine interactions with possible microbiome-altering agents in a nested case-control.
The study included 2239 hospitalized adult patients identified from a database of Amsterdam University Medical Centers between 2018 to 2021. Patients in the case group had newly detected ESBL or carbapenemase-producing Enterobacterales. Patients with negative results for ESBL- and carbapenemase-producing Enterobacterales were assigned to the control group using risk-set sampling. They were then matched on a 5:1 ratio with patients in the case group by culture, date, and age. A second validation case-control study included matched pairs (1:1 ratio; 94 in each group) of prospectively enrolled patients.
The primary exposure was PPI use and clinical data at 30 days, and the secondary exposure was at 90 days before the culture date. Adjusted incidence rate ratios of ESBL- or carbapenemase-producing Enterobacterales acquisition by time risk windows and PPI dose were estimated.
The study revealed the following findings:
- Among 2239 hospitalized patients (51.1% male; mean age, 60.9 years), 374 were in the case group (51.6% male; mean age, 61.1 years), and 1865 were in the matched control group (51.0% male; mean age, 60.9 years).
- The aIRR for PPI use overall was 1.48 at 30 days.
- Sensitivity analyses and the analysis of the pair-matched study with prospectively enrolled patients (aIRR, 2.96) yielded similar results; findings were consistent in subgroups and corroborated by a negative-control exposure analysis.
- The authors found no association with microbiome-disturbing agents; antibiotics and laxatives were independently associated with a more than 2-fold increase in acquisition risk (antibiotics: aIRR, 2.78; laxatives: aIRR, 2.26).
"Our findings support the PPI's role as an independent risk factor linked with acquiring ESBL- or carbapenemase-producing Enterobacterales," the researchers wrote. "Given the wide misuse of PPIs, its judicious use is warranted to prevent the associated acquisition of ESBL potentially- or carbapenemase-producing Enterobacterales."
Reference:
Willems RPJ, Schut MC, Kaiser AM, et al. Association of Proton Pump Inhibitor Use With Risk of Acquiring Drug-Resistant Enterobacterales. JAMA Netw Open. 2023;6(2):e230470. doi:10.1001/jamanetworkopen.2023.0470
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751